Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study provides first genomic characterization of remission in juvenile rheumatoid arthritis patients

Study provides first genomic characterization of remission in juvenile rheumatoid arthritis patients

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

Updated EULAR recommendations for management of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

Study: Women with RA exposed to anti-tumor necrosis drugs may have increased abortion rates

Study: Women with RA exposed to anti-tumor necrosis drugs may have increased abortion rates

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

FDA accepts Antares Pharma's New Drug Application for OTREXUP

FDA accepts Antares Pharma's New Drug Application for OTREXUP